WO1997028449A1 - Method of determining the hepatic status of an individual, including a liver transplant recipient - Google Patents

Method of determining the hepatic status of an individual, including a liver transplant recipient Download PDF

Info

Publication number
WO1997028449A1
WO1997028449A1 PCT/IE1996/000003 IE9600003W WO9728449A1 WO 1997028449 A1 WO1997028449 A1 WO 1997028449A1 IE 9600003 W IE9600003 W IE 9600003W WO 9728449 A1 WO9728449 A1 WO 9728449A1
Authority
WO
WIPO (PCT)
Prior art keywords
πgst
level
subject
biological fluid
human
Prior art date
Application number
PCT/IE1996/000003
Other languages
French (fr)
Inventor
John Martin Doyle
Cormac Gerard Kilty
Fiona Mary Manning
Original Assignee
Biotrin Intellectual Properties Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotrin Intellectual Properties Limited filed Critical Biotrin Intellectual Properties Limited
Priority to JP09527453A priority Critical patent/JP2000505544A/en
Priority to BR9612475A priority patent/BR9612475A/en
Priority to AT96901946T priority patent/ATE322013T1/en
Priority to DE69635979T priority patent/DE69635979T2/en
Priority to ES96901946T priority patent/ES2262153T3/en
Priority to AU46323/96A priority patent/AU712180B2/en
Priority to US09/117,476 priority patent/US6183977B1/en
Priority to EP96901946A priority patent/EP0880700B1/en
Priority to PCT/IE1996/000003 priority patent/WO1997028449A1/en
Priority to CA002246072A priority patent/CA2246072A1/en
Priority to HU9903578A priority patent/HUP9903578A2/en
Priority to CZ19982288A priority patent/CZ287488B6/en
Priority to PL96328518A priority patent/PL328518A1/en
Publication of WO1997028449A1 publication Critical patent/WO1997028449A1/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Definitions

  • This invention relates to a method of determining the hepatic status of a subject, including a liver transplant recipient and, thereby, deciding on appropriate therapy or corrective action, if required, dependent on said hepatic status.
  • Glutathione S-transferases comprise a multigene family of proteins consisting mainly of alpha ( ⁇ GST), mu ( ⁇ GST), pi ( ⁇ GST) and theta-class ( ⁇ GST) isoforms as defined by isoelectric point and are responsible for the detoxification of a range of xenobiotics, mainly via conjugation to glutathione (Beckett, G.J and Hayes, J.D., Advances in Clinical Chemistry (1993); 30, 281 -380).
  • the proteins are dimeric in nature consisting of two 25-27kDa subunits and may exist in homodimeric or heterodimeric forms.
  • Pi Glutathione S-transferase is a homodimer, and is located in the cytoplasm of bile duct epithelial cells within the liver (Beckett G.J. and Hayes, J.D., (1993) supra).
  • ⁇ GST is known to be present in hepatocytes within the liver and exists in both homodimeric and heterodimeric states (Campbell, J.A.H., et. al, Cancer (Philadelphia) (1991) 67, 1608-1613; Howie,
  • EP-A 0 640 145 discloses a method which assists in the early diagnosis of rejection in a liver transplant recipient and which comprises measuring an increase in plasma or serum ⁇ GST from the recipient in the absence of or preceding any change in plasma or serum transaminase.
  • ⁇ GST has received no attention as a potential marker of graft rejection, a fact possibly due to the low levels of enzyme present in the biliary epithelial cells of the liver.
  • ⁇ and ⁇ GST are present in bile from both normal individuals and people suffering from specific cancers (e.g.,cholangiocarcinoma) as measured by radio-immunoassay (Howie. A.F., et. al., Clin. Chem. Acta. (1989) 184, 269-278).
  • ⁇ GST may have a role in the prediction of transplanted liver rejection or other liver/biliary disorders.
  • graft injury occurs due to viral infection (e.g., Hepatitis C re-infection or cytomegaiovirus (CMV)
  • CMV cytomegaiovirus
  • excess immunosuppresive agents e.g., cyclosporin A or FK506
  • failure to recognise genuine rejection from non-specific graft injury could lead to delay in augmentation of immunosuppressive therapy and ultimately lead to graft removal.
  • the invention provides a method of determining the hepatic status of a subject, which method comprises measuring the level of the pi glutathione S-transferase ( ⁇ GST) isoform in a sample of a biological fluid from said subject by an immunoassay specific for the ⁇ GST isoform, comparing the level of ⁇ GST measured with the normal range of ⁇ GST in said biological fluid and, when an increase in ⁇ GST level relative to said normal range is detected, determining the hepatic status of the subject based on the level of ⁇ GST in said biological fluid.
  • ⁇ GST pi glutathione S-transferase
  • the subject is suitably a liver transplant recipient and the hepatic status is determined post-transplantation.
  • the invention has particular application in the case of liver transplantation because it enables one to determine at a very early stage post-transplantation a likelihood of rejection because the primary graft rejection generally occurs in the biliary tree within the liver as stated above. Accordingly, even earlier detection of liver transplant rejection is possible with the method according to the invention relative to the method described and claimed in EP-A 0 640 145.
  • the recipient is a human.
  • the immunoassay is preferably an enzyme immunoassay, more especially a sandwich enzyme immunoassay.
  • the method according to the invention can be used to measure ⁇ GST in a range of media, but especially in bile, plasma and serum.
  • biological fluid herein is meant for example body fluids such as bile, plasma, serum and urine as well as tissue support media and perfusates.
  • body fluids such as bile, plasma, serum and urine as well as tissue support media and perfusates.
  • the biological fluids herein are also referred to generally as matrices.
  • the method according to the invention facilitates for the first time detection of the ⁇ GST isoenzyme level in bile.
  • the normal ⁇ GST level is less than 15 ⁇ g/L.
  • the normal ⁇ GST level is less than 100 ⁇ g/L.
  • the sample is diluted with a diluent which contains an effective amount of a protein which optimises antibody-antigen reactions.
  • the diluent includes Tween 20 conventionally used as a standard reagent in such immunometric methods that incorrect ⁇ GST concentrations are detected.
  • Tween 20 conventionally used as a standard reagent in such immunometric methods that incorrect ⁇ GST concentrations are detected.
  • one uses an effective amount of a protein which optimises antibody-antigen reactions one can achieve a linear titration as shown in Example 6.
  • the protein is a serum albumin such as bovine serum albumin or human serum albumin.
  • the immunoassay method according to the invention can be completed within 2.5 hours as hereinafter described in Examples. This is considerably faster than any commercially available assay for the quantitation of ⁇ GST.
  • the invention thus provides in one embodiment an immunoassay capable of being completed in under 2.5 hours which is based on the sequential addition of sample, antibody-enzyme conjugate and substrate to microtitre wells or other surface coated with monoclonal anti- ⁇ GST IgG.
  • the resultant colour intensity is proportional to the amount of ⁇ GST present in the sample and the assay range is 0-100 ⁇ g/L.
  • the assay range is readily extended by increased sample dilution.
  • the level of the alpha glutathione S-transferase ( ⁇ GST) isoform is measured in a sample of a biological fluid from said subject so as to facilitate differentiation between graft rejection and non-specific hepatocellular damage in said subject.
  • the invention also provides a test kit or pack containing one or more components for carrying out a method as hereinabove defined.
  • Fig. 1 is a schematic diagram of the sandwich enzyme immunoassay of Example 1 ;
  • Fig. 2 is a plot of absorbance at 450/630 nm versus log ⁇ GST concentration ( ⁇ g/L) according to the enzyme immunoassay for human ⁇ GST described in Example 1 ;
  • Fig. 3 is an SDS-PAGE analysis of human ⁇ , ⁇ and ⁇ GST;
  • Fig. 4 is an immunoblot analysis of human ⁇ GST
  • Fig. 5 is a plot of ⁇ GST and ⁇ GST (ng/ml) in bile versus time after reperfusion (hours) for a number of patients;
  • Fig. 6 is a plot of ⁇ GST concentration versus time (days) for a number of patients.
  • Fig. 7 is a plot of AST/ALT (U/L) and ⁇ GST and ⁇ GST (ng/ml) versus days after transplantation for a single patient.
  • ⁇ GST was purified from human placenta by affinity chromatography. Precise details of the purification procedure are as follows:
  • a. 325g of human placenta was homogenised for 2 minutes in homogenisation buffer, at a ratio of one part placenta to three parts buffer, using a Waring (Waring is a Trade Mark) blender.
  • the homogenisation buffer had the following composition:
  • Leupeptin 2 ⁇ g/ml
  • Pepstatin 2 ⁇ g/ml
  • Glutathione (GSH)- Sepharose Affinity column previously equilibrated in 20mM Tris-HCl with 200mM NaCl, pH 7.8. Equilibration buffer was reapplied to elute unbound protein. Finally 50mM Tris-HCl pH 9.5 containing 5mM GSH was used to elute bound GST from the affinity column.
  • Purified human ⁇ GST was injected into New Zealand White rabbits subcutaneously (s.c.) according to the time schedule given below and serum evaluated for anti- ⁇ GST reactivity. Once the IgG [anti-human ⁇ GST] titre was sufficient as determined by semi- quantitative dot blot analysis, the animals were exsanguinated and serum collected. Total IgG was purified from rabbit serum by Protein A affinity chromatography and was used for conjugation to horseradish peroxidase (HRP). Monoclonal IgG [anti-human ⁇ GST] as ascites, was obtained from The University Hospital, Nijmegen, The Netherlands and was not purified further prior to use.
  • HRP horseradish peroxidase
  • Murine IgG fanti-human ⁇ GSTI was used to probe nitrocellulose membranes containing immobilised human ⁇ , ⁇ and ⁇ GST.
  • the method used for immunoblot detection was as follows:
  • Human ⁇ , ⁇ and ⁇ GST (0.5 ⁇ g/track) were electrophoresed on 15% SDS-PAGE with molecular weight markers also included.
  • the polyacrylamide gel was cut and one half stained for protein while the remainder was used for electrophoretic transfer onto nitrocellulose.
  • nitrocellulose membranes were blocked for 1 hour with 5%(w/v) Marvel (Marvel is a Trade Mark) in phosphate buffered saline containing 0.05%(w/v) TWEEN-20 (PBST)- blocking buffer.
  • nitrocellulose membranes were then washed in PBST (2x for 5 min each).
  • Anti rabbit IgG-HRP conjugate was then prepared ( 1/1000 in 1 % (w/v) Marvel in PBST and added to 4(i) above.
  • Anti murine IgG-HRP conjugate was also prepared ( 1/1000) and added to 4(ii) above.
  • Diaminobenzidine substrate was then prepared and added to the membrane.
  • Anti ⁇ GST IgG-HRP conjugates were synthesised using thioether conjugation methodology.
  • Reactive maleimide groups were introduced onto IgG molecules using SMCC (succinimidyl 4-(N-maleimidomethyl) cyclohexane 1 -carboxylate) and masked sulphydryl groups were linked to HRP.
  • SMCC succinimidyl 4-(N-maleimidomethyl) cyclohexane 1 -carboxylate
  • HRP masked sulphydryl groups were linked to HRP.
  • the maleimide-activated IgG and HRP-SH were mixed together and allowed to react for 4.5 hours.
  • the resultant IgG-HRP conjugate, formed by covalent thioether linkage was brought to 50% (v/v) glycerol and stored at -20°C for use in the El A of Example 1.
  • the format of the immunoassay for the quantitative detection of human ⁇ GST is a conventional sandwich format as depicted schematically in Fig. 1 , and described below.
  • a Nunc Maxisorp (Nunc Maxisorp is a Trade Mark) microtitre plate was coated with murine monoclonal IgG [anti-human ⁇ GST] (referred to in Preparatory Example B) immobilised via goat F(ab) 2 fragments [anti-mouse IgG].
  • This method of antibody coating serves to orientate Mab binding sites and also improves assay sensitivity by minimising adherence - induced denaturation of the capture antibody.
  • IgG [anti-human ⁇ GST]-HRP conjugates in association with tetramethylbenzidine substrate (TMB), were used to facilitate detection of captured/immobilised ⁇ GST.
  • TMB tetramethylbenzidine substrate
  • the total assay time was found to be 2 hours 15 minutes and assay conditions included microtitre plate shaking at fixed temperature during the sample and conjugate incubation steps, respectively.
  • the TMB substrate incubation required fixed temperature conditions only.
  • Fig. 3 illustrates the purity of human ⁇ GST obtained by the procedure of Preparatory Example A prior to immunisation into rabbits and confirms the absence of any other human derived proteins which might otherwise contribute to reduced assay specificity.
  • Fig. 3 illustrates the purity of human ⁇ GST obtained by the procedure of Preparatory Example A prior to immunisation into rabbits and confirms the absence of any other human derived proteins which might otherwise contribute to reduced assay specificity.
  • Lane 2 molecular weight markers.
  • HCC hepatocellular carcinoma
  • PBC primary biliary cirrhosis
  • BDS bile duct stones
  • HCC hepatocellular carcinoma
  • PBC primary biliary cirrhosis
  • Serial bile and plasma samples were collected from patients following liver transplant operations and assayed for both ⁇ and ⁇ GST respectively.
  • the patients exhibited a range of post-operative conditions, from uneventful recovery, to acute rejection and Hepatitis C re-infection, which are normally associated with transplantation.
  • ⁇ GST concentrations of both ⁇ and ⁇ GST in bile were monitored simultaneously.
  • ⁇ GST was measured according to the procedure described in EP-A 0 640 145. During an uneventful recovery, ⁇ GST could be detected as soon as 2 hours post transplantation, and levels remained low (i.e. below 50 ⁇ g/L). ⁇ GST levels were initially high due to reperfusion injury, but returned to baseline levels within 2 days as shown in Fig. 5. This figure shows the typical course of ⁇ and ⁇ GST during and after human liver transplantation. ⁇ GST levels remain low. Complications associated with liver transplantation could also be identified. One of the major risks is acute rejection, or the even more serious, steroid-resistant rejection.
  • ⁇ GST levels sustained over a period of days as shown in Fig. 6.
  • SR steroid-resistant rejection
  • AR acute rejection
  • liver/biliary damage hepatocellular carcinoma and primary biliary cirrhosis
  • samples from donor bile, and post liver transplantation were assayed for human ⁇ GST according to the protocol of Example 1.
  • Both polyclonal and monoclonal antibodies were coated onto the solid phase for use as a capture antibody. Direct coating of the both the polyclonal and the monoclonal antibodies resulted in very low absorbance readings for the standard curve (see Table 5). When immobilisation was achieved via a linker antibody (goat anti- mouse/anti-rabbit IgG), a significant increase in O.D. values was obtained for the monoclonal antibody. However, no such increase was observed for the polyclonal antibody.
  • Direct coating of the antibody onto the solid phase (2 ⁇ g/mL) was compared to coating via a linker antibody (goat anti species, at 2 ⁇ g/ml). with the anti ⁇ GST antibody at a fixed concentration.

Abstract

A method of determining the hepatic status of a subject comprises measuring the level of the pi glutathione S-transferase (πGST) isoform in a sample of a biological fluid from the subject by an immunoassay specific for the πGST isoform, comparing the level of πGST measured with the normal range of πGST in the biological fluid and, when an increase in πGST level relative to the normal range is detected, determining the hepatic status of the subject based on the level of πGST in the biological fluid. The method has particular application in the case of liver transplantation enabling one to determine at a very early stage post-transplantation a likelihood of rejection because the primary graft rejection generally occurs in the biliary tree.

Description

Method of determining the hepatic status of an individual. including a liver transplant recipient
Technical Field
This invention relates to a method of determining the hepatic status of a subject, including a liver transplant recipient and, thereby, deciding on appropriate therapy or corrective action, if required, dependent on said hepatic status.
Background Art
The ability to differentiate between the various types of hepatic injury is of great significance in the treatment of both transplant patients and also individuals who suffer from other hepatic diseases which may affect the biliary system.
Glutathione S-transferases (GSTs) comprise a multigene family of proteins consisting mainly of alpha (αGST), mu (μGST), pi (πGST) and theta-class (ΘGST) isoforms as defined by isoelectric point and are responsible for the detoxification of a range of xenobiotics, mainly via conjugation to glutathione (Beckett, G.J and Hayes, J.D., Advances in Clinical Chemistry (1993); 30, 281 -380). Generally, the proteins are dimeric in nature consisting of two 25-27kDa subunits and may exist in homodimeric or heterodimeric forms. Pi Glutathione S-transferase (πGST) is a homodimer, and is located in the cytoplasm of bile duct epithelial cells within the liver (Beckett G.J. and Hayes, J.D., (1993) supra). αGST is known to be present in hepatocytes within the liver and exists in both homodimeric and heterodimeric states (Campbell, J.A.H., et. al, Cancer (Philadelphia) (1991) 67, 1608-1613; Howie,
A.F., et. al., Clin. Chem. Acta., (1988) 177, 65-76). This heterogenous GST distribution of α and πGST suggests that the different isoenzymes have unique in vivo functions in different hepatic regions (Campbell, J.A.H., et. al., (1991) supra). EP-A 0 640 145 discloses a method which assists in the early diagnosis of rejection in a liver transplant recipient and which comprises measuring an increase in plasma or serum αGST from the recipient in the absence of or preceding any change in plasma or serum transaminase. Thus, it has been conclusively demonstrated that measurement of the plasma αGST level facilitates monitoring of the post-transplant hepatic status by acting as an extremely sensitive, although not totally specific marker of graft rejection.
It is notable that πGST has received no attention as a potential marker of graft rejection, a fact possibly due to the low levels of enzyme present in the biliary epithelial cells of the liver. There is some evidence, however, that α and πGST are present in bile from both normal individuals and people suffering from specific cancers (e.g.,cholangiocarcinoma) as measured by radio-immunoassay (Howie. A.F., et. al., Clin. Chem. Acta. (1989) 184, 269-278). Additionally, some authors have referenced the fact that measurement of serum and plasma πGST levels may facilitate diagnosis of malignant tumours since πGST appears to be specifically expressed in malignant tissue (Niitsu, Y., et al, Cancer ( 1989) 63, 317-323; Howie, A.F., et. al., Clin. Chem. (1990) 36(3), 453-456. and Hida, T., et al., Cancer ( 1994) 73(5), 1377- 1382. None of the aforementioned authors allude to the fact that πGST may have a role in the prediction of transplanted liver rejection or other liver/biliary disorders.
Since it is known that primary graft rejection generally occurs in the biliary tree within the liver (Ascher, N., (1993) In 'Immunology of liver transplantation' Neuberger, J. and Adams, D. (eds)), it would appear that specific measurement of biliary or plasma πGST levels may allow diagnosis of early rejection or facilitate discrimination between post-transplant hepatocellular or biliary damage. The importance of distinguishing between non-specific hepatic injury and graft rejection cannot be overstated since the treatment for each condition is entirely different. Furthermore, initiation of the incorrect treatment could be extremely deleterious to the health of an individual already severely ill. For example, if graft injury occurs due to viral infection (e.g., Hepatitis C re-infection or cytomegaiovirus (CMV), it is necessary to carefully monitor the levels of anti-rejection immunosuppression treatment since excess immunosuppresive agents (e.g., cyclosporin A or FK506) would significantly impair the ability to fight viral infection. Conversely, failure to recognise genuine rejection from non-specific graft injury could lead to delay in augmentation of immunosuppressive therapy and ultimately lead to graft removal.
Accordingly, there is a need for methods of determining the hepatic status of an individual in various disease states or abnormal conditions of the liver.
Disclosure of Invention
The invention provides a method of determining the hepatic status of a subject, which method comprises measuring the level of the pi glutathione S-transferase (πGST) isoform in a sample of a biological fluid from said subject by an immunoassay specific for the πGST isoform, comparing the level of πGST measured with the normal range of πGST in said biological fluid and, when an increase in πGST level relative to said normal range is detected, determining the hepatic status of the subject based on the level of πGST in said biological fluid.
By providing a further method for determining hepatic status based on a marker specific to a particular hepatic site greatly facilitates the treatment of patients with various disease states and other abnormal conditions of the liver as hereinafter described in greater detail.
The subject is suitably a liver transplant recipient and the hepatic status is determined post-transplantation.
The invention has particular application in the case of liver transplantation because it enables one to determine at a very early stage post-transplantation a likelihood of rejection because the primary graft rejection generally occurs in the biliary tree within the liver as stated above. Accordingly, even earlier detection of liver transplant rejection is possible with the method according to the invention relative to the method described and claimed in EP-A 0 640 145.
Preferably, the recipient is a human.
The immunoassay is preferably an enzyme immunoassay, more especially a sandwich enzyme immunoassay.
The method according to the invention can be used to measure πGST in a range of media, but especially in bile, plasma and serum.
By biological fluid herein is meant for example body fluids such as bile, plasma, serum and urine as well as tissue support media and perfusates. The biological fluids herein are also referred to generally as matrices.
The method according to the invention facilitates for the first time detection of the πGST isoenzyme level in bile.
When the biological fluid is bile, the normal πGST level is less than 15 μg/L.
When the biological fluid is plasma, the normal πGST level is less than 100 μg/L.
As demonstrated hereinbelow care should be taken when the method is carried out on plasma that the plasma is collected and stored prior to the determination in the presence of an anti-coagulant under conditions which permit substantially no haemolysis to occur during said storage period.
We have found that use of fluoro-oxylate tubes results in a high degree of haemolysis releasing πGST from erythrocytes which gives falsely elevated levels of πGST. Other GST isoenzymes are either not found in the blood or are present at extremely low levels. For example, μGST is present in leucocytes. However, it is not clear from the literature as to whether it is present in erythrocytes. In any event. μGST is only present in 50% of the population. ΘGST expresses a similar inter-individual variability as does μGST and if present in blood is present at extremely low levels. αGST is not present in blood to any great extent.
In a preferred embodiment, the sample is diluted with a diluent which contains an effective amount of a protein which optimises antibody-antigen reactions.
We have found that if the diluent includes Tween 20 conventionally used as a standard reagent in such immunometric methods that incorrect πGST concentrations are detected. We have found that if one uses an effective amount of a protein which optimises antibody-antigen reactions, one can achieve a linear titration as shown in Example 6.
Suitably, the protein is a serum albumin such as bovine serum albumin or human serum albumin.
The immunoassay method according to the invention can be completed within 2.5 hours as hereinafter described in Examples. This is considerably faster than any commercially available assay for the quantitation of πGST.
The invention thus provides in one embodiment an immunoassay capable of being completed in under 2.5 hours which is based on the sequential addition of sample, antibody-enzyme conjugate and substrate to microtitre wells or other surface coated with monoclonal anti-πGST IgG. The resultant colour intensity is proportional to the amount of πGST present in the sample and the assay range is 0-100 μg/L. The assay range is readily extended by increased sample dilution.
According to another embodiment of the invention, additionally the level of the alpha glutathione S-transferase (αGST) isoform is measured in a sample of a biological fluid from said subject so as to facilitate differentiation between graft rejection and non-specific hepatocellular damage in said subject.
The invention also provides a test kit or pack containing one or more components for carrying out a method as hereinabove defined.
Brief Description of Drawings
In the accompanying drawings:
Fig. 1 is a schematic diagram of the sandwich enzyme immunoassay of Example 1 ;
Fig. 2 is a plot of absorbance at 450/630 nm versus log πGST concentration (μg/L) according to the enzyme immunoassay for human πGST described in Example 1 ;
Fig. 3 is an SDS-PAGE analysis of human μ, α and πGST;
Fig. 4 is an immunoblot analysis of human πGST;
Fig. 5 is a plot of αGST and πGST (ng/ml) in bile versus time after reperfusion (hours) for a number of patients;
Fig. 6 is a plot of πGST concentration versus time (days) for a number of patients; and
Fig. 7 is a plot of AST/ALT (U/L) and αGST and πGST (ng/ml) versus days after transplantation for a single patient.
Modes for Carrying Out the Invention
The invention will be further illustrated by the following Examples. Preparatory Example A
Purification of human πGST
πGST was purified from human placenta by affinity chromatography. Precise details of the purification procedure are as follows:
a. 325g of human placenta was homogenised for 2 minutes in homogenisation buffer, at a ratio of one part placenta to three parts buffer, using a Waring (Waring is a Trade Mark) blender. The homogenisation buffer had the following composition:
Figure imgf000009_0001
250mM Sucrose 5mM EDTA pH 7.8
2μg/ml Leupeptin 2μg/ml Pepstatin.
b. The placenta homogenate was centrifuged at lOOOOg for 60 minutes.
c. The supernatant was then loaded on a Glutathione (GSH)- Sepharose Affinity column previously equilibrated in 20mM Tris-HCl with 200mM NaCl, pH 7.8. Equilibration buffer was reapplied to elute unbound protein. Finally 50mM Tris-HCl pH 9.5 containing 5mM GSH was used to elute bound GST from the affinity column.
d. The eluted material was then dialysed against 0.1M PBS.
Preparatory Example B
Antibody Production and Purification:
Purified human πGST was injected into New Zealand White rabbits subcutaneously (s.c.) according to the time schedule given below and serum evaluated for anti-πGST reactivity. Once the IgG [anti-human πGST] titre was sufficient as determined by semi- quantitative dot blot analysis, the animals were exsanguinated and serum collected. Total IgG was purified from rabbit serum by Protein A affinity chromatography and was used for conjugation to horseradish peroxidase (HRP). Monoclonal IgG [anti-human πGST] as ascites, was obtained from The University Hospital, Nijmegen, The Netherlands and was not purified further prior to use.
Immunisation Schedule ( general):
Day 1: A test bleed of 5ml of preserum was taken from the ear of the rabbit. 0.5ml of human πGST antigen ( lOOμg) was mixed with an equal volume of Freund's Complete Adjuvant. The mixture of antigen and adjuvant was homogenised to ensure a good emulsion. This mixture was then injected subcutaneously into multiple sites on the back of the rabbit which had previously been shaved.
Day 28: A test bleed of 5ml of serum was taken from the ear of the rabbit. 0.5ml antigen ( lOOμg) was mixed with an equal volume of Freund's Incomplete Adjuvant. The antigen/adjuvant mixture was homogenised to ensure a good emulsion. This mixture was then injected subcutaneously into multiple sites on the back of the rabbit.
Day 42: A test bleed of 10ml of blood was taken from the rabbit's ear.
Day 56: A second boost was given to the rabbit as described on Day 28.
Day 70: A test bleed of 10ml of blood was taken from the ear of the rabbit. When the titre was sufficiently high, the rabbit was sacrificed and as much blood as possible collected. Preparatory Example C
Immunoblotting:
All polyclonal and monoclonal IgGs for use in the followings Examples were checked for πGST reactivity and potential cross- reactivity against human α and μGST respectively, via the following immunoblot combinations:-
(a) Rabbit IgG [anti-human πGSTI was used to probe nitrocellulose membranes containing immobilised human α. π and μGST.
(b) Murine IgG fanti-human πGSTI was used to probe nitrocellulose membranes containing immobilised human α, π and μGST.
The method used for immunoblot detection was as follows:
1. Human α, π and μGST (0.5μg/track) were electrophoresed on 15% SDS-PAGE with molecular weight markers also included.
2. After electrophoresis, the polyacrylamide gel was cut and one half stained for protein while the remainder was used for electrophoretic transfer onto nitrocellulose.
3. After electrophoretic transfer, the nitrocellulose membranes were blocked for 1 hour with 5%(w/v) Marvel (Marvel is a Trade Mark) in phosphate buffered saline containing 0.05%(w/v) TWEEN-20 (PBST)- blocking buffer.
4. The following solutions were then prepared:
(i) Rabbit IgG [anti-human πGST] in l%(w/v) Marvel in PBST (ii) Murine IgG [anti-human πGST] in l %(w/v) Marvel in PBST
and added to the membranes once blocking buffer was decanted.
Incubation with antibody solutions was allowed to proceed for one hour.
5. The nitrocellulose membranes were then washed in PBST (2x for 5 min each).
6. Anti rabbit IgG-HRP conjugate was then prepared ( 1/1000 in 1 % (w/v) Marvel in PBST and added to 4(i) above. Anti murine IgG-HRP conjugate was also prepared ( 1/1000) and added to 4(ii) above.
7. After one hour incubation with anti-species conjugates, the reagents were discarded and the membranes washed as in 5 above.
8. Diaminobenzidine substrate was then prepared and added to the membrane.
A positive reaction was indicated by a brown precipitate on the nitrocellulose membrane.
Preparatory Example D
Anti πGST IgG-horseradish peroxidase (HRP) conjugate synthesis:
Anti πGST IgG-HRP conjugates were synthesised using thioether conjugation methodology. (Duncan, R.J.S., et al., (1983); Anal. Biochem. 132, 68-73) Reactive maleimide groups were introduced onto IgG molecules using SMCC (succinimidyl 4-(N-maleimidomethyl) cyclohexane 1 -carboxylate) and masked sulphydryl groups were linked to HRP. After a demasking step to produce reactive sulphydryl groups, the maleimide-activated IgG and HRP-SH were mixed together and allowed to react for 4.5 hours. The resultant IgG-HRP conjugate, formed by covalent thioether linkage, was brought to 50% (v/v) glycerol and stored at -20°C for use in the El A of Example 1.
Example 1
Sandwich enzyme immunoassay
The format of the immunoassay for the quantitative detection of human πGST is a conventional sandwich format as depicted schematically in Fig. 1 , and described below.
a. A Nunc Maxisorp (Nunc Maxisorp is a Trade Mark) microtitre plate was coated with murine monoclonal IgG [anti-human πGST] (referred to in Preparatory Example B) immobilised via goat F(ab)2 fragments [anti-mouse IgG]. This method of antibody coating serves to orientate Mab binding sites and also improves assay sensitivity by minimising adherence - induced denaturation of the capture antibody.
b. Human πGST, purified from placenta as described in Preparatory Example A, was used as the assay calibrator.
c. IgG [anti-human πGST]-HRP conjugates, in association with tetramethylbenzidine substrate (TMB), were used to facilitate detection of captured/immobilised πGST.
d. The enzyme reaction was stopped by the addition of IN H2SO4 and the absorbance measured at 450nm using 630nm as a reference wavelength. Colour intensity was proportional to πGST concentration and after generating a plot of A45o 63θnm versus concentration (μg/L), the concentration of unknown samples can be determined (see Fig. 2). Total assay time was less than 2.5 hours.
The total assay time was found to be 2 hours 15 minutes and assay conditions included microtitre plate shaking at fixed temperature during the sample and conjugate incubation steps, respectively. The TMB substrate incubation required fixed temperature conditions only.
Example 2
Collection of plasma for πGST analysis
The effect of a variety of commonly used anti-coagulants
(ethylenediaminetetraacetic acid (EDTA), lithium heparin, sodium citrate and fluoro-oxylate) and other plasma collection tubes (containing platelet inhibitors) on πGST levels in plasma, was examined. Samples were collected by venipuncture into tubes containing the particular anticoagulant. Plasma was separated by centrifugation (6,000g for 10 min), and residual platelets were removed by an additional centrifugation step (10,000g for 10 min). The supernatant was removed, and samples were assayed using the protocol described in Example 1.
Plasma was collected from a number of individuals into a series of plasma collection tubes. Each sample was handled as described above, and the release of πGST into plasma was monitored over a 24 hour period. Table 1 below shows the πGST levels in plasma from the same individual collected into four different plasma collection tubes, assayed at TO and T24. The results show that there is no significant difference in πGST concentrations in plasma collected in the presence of any of the above anti-coagulants. There does not appear to be a significant increase in πGST concentrations (caused by release of πGST from erythrocytes or platelets) when the unseparated plasma is stored for up to 24 hours. The exception is the fluoro-oxylate tubes where a large degree of haemolysis occurred, releasing πGST from erythrocytes, and giving falsely elevated levels of the protein as shown in Table 1. Table 1
Comparison of the influence of anti-coagulants in plasma collection tubes for πGST analvsis in plasma. Values are given in μg/L.
Patient EDTA Li/Hep Na citrate FI oxylate
TO T24 TO T24 TO T24 TO T24
1 171.9 220.2 199.4 194.7 167.5 220.3 170.0 >500
2 65.6 70.5 62.8 88.4 53.2 65.4 55.4 >500
3 59.6 78.6 65.4 88.6 53.7 68.4 59.9 >500
4 81.7 92.8 90.2 1 19.5 74.9 122.1 81.2 >500
5 46.7 67.5 44.6 73.3 28.9 68.6 60.9 >500
It can be seen from Table 1 that there is no significant difference between the concentration of πGST in plasma collected in the presence of any of the above anti-coagulants.
Example 3
Assessment of purity of immunoassay reagents
Fig. 3 illustrates the purity of human πGST obtained by the procedure of Preparatory Example A prior to immunisation into rabbits and confirms the absence of any other human derived proteins which might otherwise contribute to reduced assay specificity. In Fig. 3:
Lane 1 = μGST Lane 2 = αGST
Lane 3 = πGST Lane 4 = molecular weight markers.
Immunoblot analysis of the monoclonal antibody reactivity revealed that the IgG[anti-human πGST] was highly specific for human πGST and did not exhibit any significant cross-reactivity with human α or μGST. The results are shown in Fig. 4. Lane 1 = πGST
Lane 2 = molecular weight markers.
A finding supported by the lack of α and μGST reactivity in the human πGST-specific enzyme immunoassay as shown in Table 2.
Table 2
Evaluation of human αGST and μGST reactivity in the enzvme immunoassay for the detection of human πGST.
Figure imgf000016_0001
It is clear from Table 2 that no cross-reactivity is evident for either αGST or μGST in this assay.
The significance of this fact is of utmost importance since it implies that the enzyme immunoassay for human πGST quantitation is specific for the detection of human πGST. Thus, any human πGST present in samples can be specifically detected without cross- contamination from other GSTs.
Example 4
πGST quantitation in bile
A number of bile samples from patients with specific liver/biliary damage were tested in the assay for human πGST. Patients with hepatocellular carcinoma (HCC) and primary biliary cirrhosis (PBC) were found to contain very high levels of πGST. A patient with bile duct stones (BDS) was also found to have increased πGST levels, but not as elevated as those for HCC and PBC as shown in Table 3.
Table 3
πGST concentrations in bile from patients with hepatocellular carcinoma (HCC), primary biliary cirrhosis (PBC) and bile duct stone
(BDS).
Condition [πGST] (μg/L)
HCC 5357
PBC 2432
BDS 506.6
All of these samples show significantly elevated πGST levels.
Example 5
Clinical utility of πGST quantitation
Serial bile and plasma samples were collected from patients following liver transplant operations and assayed for both π and αGST respectively. The patients exhibited a range of post-operative conditions, from uneventful recovery, to acute rejection and Hepatitis C re-infection, which are normally associated with transplantation.
A number of significant trends were observed when the concentrations of both π and αGST in bile were monitored simultaneously. αGST was measured according to the procedure described in EP-A 0 640 145. During an uneventful recovery, πGST could be detected as soon as 2 hours post transplantation, and levels remained low (i.e. below 50 μg/L). αGST levels were initially high due to reperfusion injury, but returned to baseline levels within 2 days as shown in Fig. 5. This figure shows the typical course of α and πGST during and after human liver transplantation. πGST levels remain low. Complications associated with liver transplantation could also be identified. One of the major risks is acute rejection, or the even more serious, steroid-resistant rejection. We have found that in these particular cases, there was a significant increase in πGST levels sustained over a period of days as shown in Fig. 6. This figure shows πGST levels during episodes of steroid-resistant rejection (SR) and acute rejection (AR). Levels are elevated and remain high over a period of at least 20 days. αGST levels were also high, but they returned to baseline levels within a period of 5-8 days.
The possibility of infection or re-infection is another serious risk involved in transplantation. We have seen that in episodes of HCV re¬ infection, very high levels of αGST were observed over a sustained period of time (i.e. at least 25 days). However, πGST levels remained near normal as shown in Fig. 7. This contrasts sharply with the previous cases of acute rejection, where the reverse was true. Thus, by the simultaneous quantitation of α and πGST, it was possible to successfully differentiate between acute rejection and HCV re-infection, something which has previously proved to be very difficult, and has posed a therapeutic dilemma to transplant surgeons.
Example 6
Linearity of dilution of bile samples
A number of bile samples were obtained from patients with specific liver/biliary damage (hepatocellular carcinoma and primary biliary cirrhosis), as well as samples from donor bile, and post liver transplantation. These samples were assayed for human πGST according to the protocol of Example 1.
A number of standard diluents were used as sample diluents for the titration of the bile samples. These diluents are routinely used in many assay systems, with Tween-20 being the most commonly used detergent. We have found however that the presence of this particular detergent in the sample diluent caused erroneous results. Falsely high concentrations of πGST were observed in samples diluted in Tween-20- containing diluents, caused by insufficient titration as shown in Table 4. In the absence of Tween-20, linear titration was observed. Therefore. a critical factor of this assay is the absence of Tween-20 (a standard reagent) in the sample diluent, as falsely elevated levels of πGST would be observed if it were used.
Table 4
Comparison of the titration of a PBC bile sample in diluents with and without Tween-20. Values are given in μg/L.
Dilution - Tween-20 + Tween-20
1/50 2344 3074
1/100 2374 5187
1/200 2410 7059
Linear titration was observed only in the diluent without Tween-20.
Example 7
Comparison of Polvclonal and Monoclonal Antibodies as coating antibodies
Polyclonal and monoclonal anti-human πGST IgG were immobilised onto Nunc Maxisorp plates either directly or via a linker (F(ab)2 fragments of goat anti-species IgG). Standards of known concentrations of human πGST were then run as described in Example 1 and the absorbances at similar immobilised IgG concentrations compared.
Both polyclonal and monoclonal antibodies were coated onto the solid phase for use as a capture antibody. Direct coating of the both the polyclonal and the monoclonal antibodies resulted in very low absorbance readings for the standard curve (see Table 5). When immobilisation was achieved via a linker antibody (goat anti- mouse/anti-rabbit IgG), a significant increase in O.D. values was obtained for the monoclonal antibody. However, no such increase was observed for the polyclonal antibody.
Table 5
Comparison of coating methods for the detection of human πGST.
[πGST] DIRECT COATING COATING via LINKER ANTIBODY
Polvclonal Monoclonal Polvclonal Monoclonal
Ab.
100 0.625 0.421 0.352 .557
0 0.044 0.038 0.235 0.095
Direct coating of the antibody onto the solid phase (2 μg/mL) was compared to coating via a linker antibody (goat anti species, at 2 μg/ml). with the anti πGST antibody at a fixed concentration.

Claims

Claims:-
1 . A method of determining the hepatic status of a subject, which method comprises measuring the level of the pi glutathione S- transferase (πGST) isoform in a sample of a biological fluid from said subject by an immunoassay specific for the πGST isoform. comparing the level of πGST measured with the normal range of πGST in said biological fluid and, when an increase in πGST level relative to said normal range is detected, determining the hepatic status of the subject based on the level of πGST in said biological fluid.
2. A method according to Claim I . wherein the subject is a liver transplant recipient and the hepatic status is determined post- transplantation.
3. A method according to Claim 1 or 2, wherein the subject is a human.
4. A method according to any preceding claim, wherein the immunoassay is an enzyme immunoassay.
5. A method according to any preceding claim, wherein the biological fluid is bile and the normal πGST level is less than 15 μg/L.
6. A method according to Claim 4, wherein the biological fluid is plasma and the normal πGST level is less than 100 μg/L.
7. A method according to Claim 6, wherein the plasma is collected and stored prior to the determination in the presence of an anti-coagulant under conditions which permit substantially no haemolysis to occur during said storage period.
8. A method according to any preceding claim, wherein the sample is diluted with a diluent which contains an effective amount of a protein which optimises antibody-antigen reactions.
9. A method according to Claim 8, wherein the protein is a serum albumin.
10. A method according to any preceding claim, wherein the entire immunoassay is completed within 2.5 hours.
1 1. A method according to any one of Claims 2- 10, wherein additionally the level of the alpha glutathione S-transferase (αGST) isoform is measured in a sample of a biological fluid from said subject so as to facilitate differentiation between graft rejection and non¬ specific hepatocellular damage in said subject.
12. A test kit or pack containing one or more components for carrying out a method according to any one of Claims 1- 1 1.
PCT/IE1996/000003 1996-02-02 1996-02-02 Method of determining the hepatic status of an individual, including a liver transplant recipient WO1997028449A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP09527453A JP2000505544A (en) 1996-02-02 1996-02-02 A method for determining the liver status of individuals including liver transplant recipients
BR9612475A BR9612475A (en) 1996-02-02 1996-02-02 Method of determining a person's liver status including a liver transplant recipient
AT96901946T ATE322013T1 (en) 1996-02-02 1996-02-02 METHOD FOR DETERMINING THE HEPATIC CONDITION OF A LIVER TRANSPLANT RECIPIENT.
DE69635979T DE69635979T2 (en) 1996-02-02 1996-02-02 METHOD FOR DETERMINING THE HEPATIVE CONDITION OF A LIVER TRANSPLANT RECEIVER.
ES96901946T ES2262153T3 (en) 1996-02-02 1996-02-02 METHOD FOR DETERMINING THE HEPATIC STATE OF A LIVER TRANSPLANT RECEPTOR.
AU46323/96A AU712180B2 (en) 1996-02-02 1996-02-02 Method of determining the hepatic status of an individual, including a liver transplant recipient
US09/117,476 US6183977B1 (en) 1996-02-02 1996-02-02 Determining hepatic status of a liver transplant recipient by measuring PI glutathione S-transferase
EP96901946A EP0880700B1 (en) 1996-02-02 1996-02-02 Method of determining the hepatic status of a liver transplant recipient.
PCT/IE1996/000003 WO1997028449A1 (en) 1996-02-02 1996-02-02 Method of determining the hepatic status of an individual, including a liver transplant recipient
CA002246072A CA2246072A1 (en) 1996-02-02 1996-02-02 Method of determining the hepatic status of an individual, including a liver transplant recipient
HU9903578A HUP9903578A2 (en) 1996-02-02 1996-02-02 Method of determining the hepatic status of an individual, including a liver transplant recipient
CZ19982288A CZ287488B6 (en) 1996-02-02 1996-02-02 Method of determining state of liver functions of individual including liver implant recipient
PL96328518A PL328518A1 (en) 1996-02-02 1996-02-02 Method of determining condition of human liver, including that belonging to a liver transplant recipient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IE1996/000003 WO1997028449A1 (en) 1996-02-02 1996-02-02 Method of determining the hepatic status of an individual, including a liver transplant recipient
CA002246072A CA2246072A1 (en) 1996-02-02 1996-02-02 Method of determining the hepatic status of an individual, including a liver transplant recipient

Publications (1)

Publication Number Publication Date
WO1997028449A1 true WO1997028449A1 (en) 1997-08-07

Family

ID=25680448

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IE1996/000003 WO1997028449A1 (en) 1996-02-02 1996-02-02 Method of determining the hepatic status of an individual, including a liver transplant recipient

Country Status (13)

Country Link
US (1) US6183977B1 (en)
EP (1) EP0880700B1 (en)
JP (1) JP2000505544A (en)
AT (1) ATE322013T1 (en)
AU (1) AU712180B2 (en)
BR (1) BR9612475A (en)
CA (1) CA2246072A1 (en)
CZ (1) CZ287488B6 (en)
DE (1) DE69635979T2 (en)
ES (1) ES2262153T3 (en)
HU (1) HUP9903578A2 (en)
PL (1) PL328518A1 (en)
WO (1) WO1997028449A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492103B1 (en) 2000-01-31 2002-12-10 Organ Recovery Systems, Inc. System for organ and tissue preservation and hypothermic blood substitution
US8962303B2 (en) 1998-09-29 2015-02-24 Lifeline Scientific, Inc. Apparatus and method for maintaining and/or restoring viability of organs

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022909A1 (en) * 2001-06-05 2003-01-30 University Of Chicago Use of methylnaltrexone to treat immune suppression
AU2003297028A1 (en) * 2002-12-13 2004-07-09 St. Jude Children's Research Hospital Glutathione-s-transferase test for susceptibility to parkinson's
WO2006107846A2 (en) * 2005-04-01 2006-10-12 University Of Florida Research Foundation, Inc. Biomakers of liver injury
US8048638B2 (en) 2005-04-01 2011-11-01 University Of Florida Research Foundation, Inc. Biomarkers of liver injury
US9682132B2 (en) 2010-01-26 2017-06-20 Banyan Biomarkers, Inc Compositions and methods relating to argininosucccinate synthetase

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012088A1 (en) * 1989-04-13 1990-10-18 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce MONOCLONAL ANTIBODIES TO HUMAN GLUTATHIONE S TRANSFERASE Pi
JPH0425763A (en) * 1990-05-21 1992-01-29 Maruko Seiyaku Kk Method for determining glutathione s-transferase pi and reagent for diagnosis
WO1993022452A1 (en) * 1992-05-01 1993-11-11 Cormac Gerard Kilty Measurement of an enzyme marker as an aid to diagnosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35419E (en) * 1992-05-01 1997-01-07 Cormac G. Kilty Measurement of an enzyme marker as an aid to diagnosis of liver transplant rejection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012088A1 (en) * 1989-04-13 1990-10-18 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce MONOCLONAL ANTIBODIES TO HUMAN GLUTATHIONE S TRANSFERASE Pi
JPH0425763A (en) * 1990-05-21 1992-01-29 Maruko Seiyaku Kk Method for determining glutathione s-transferase pi and reagent for diagnosis
WO1993022452A1 (en) * 1992-05-01 1993-11-11 Cormac Gerard Kilty Measurement of an enzyme marker as an aid to diagnosis
EP0640145A1 (en) * 1992-05-01 1995-03-01 Cormac Gerard Kilty Measurement of an enzyme marker as an aid to diagnosis.

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 109, no. 25, 19 December 1988, Columbus, Ohio, US; abstract no. 225320, Y. HIRATA.: "The development of immunoradiometric assay of glutathione S-transferase (GST)-pi and its application to serodiagnosis in cancers of gastrointestinal tract." page 345; column 2; XP002014847 *
CHEMICAL ABSTRACTS, vol. 117, no. 23, 7 December 1992, Columbus, Ohio, US; abstract no. 231211, T. SATO.: "Immunohistochemical localization of human glutathione S-transferase isozymes in primary liver tumors and intrahepatic tumor-like lesions." page 599; column 2; XP002014849 *
CHEMICAL ABSTRACTS, vol. 118, no. 9, 1 March 1993, Columbus, Ohio, US; abstract no. 78246, L.ZHU ET AL.: "Detection of glutathione S-transferase in human hepatocellular carcinoma and other chronic liver disease tissue." page 560; column 2; XP002014848 *
DATABASE WPI Section Ch Week 9211, Derwent World Patents Index; Class BO4, AN 92-083782, XP002014850 *
KANZO, vol. 33, no. 5, 1992, pages 390 - 398 *
SAPPORO IGAKU ZASSHI, vol. 57, no. 3, 1988, pages 277 - 290 *
SHANGHAI YIKE DAXUE XUEBAO, vol. 19, no. 4, 1992, pages 263 - 266 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962303B2 (en) 1998-09-29 2015-02-24 Lifeline Scientific, Inc. Apparatus and method for maintaining and/or restoring viability of organs
US6492103B1 (en) 2000-01-31 2002-12-10 Organ Recovery Systems, Inc. System for organ and tissue preservation and hypothermic blood substitution
US6994954B2 (en) 2000-01-31 2006-02-07 Organ Recovery Systems, Inc. System for organ and tissue preservation and hypothermic blood substitution

Also Published As

Publication number Publication date
DE69635979D1 (en) 2006-05-18
DE69635979T2 (en) 2006-11-16
JP2000505544A (en) 2000-05-09
CZ228898A3 (en) 1999-03-17
CZ287488B6 (en) 2000-12-13
BR9612475A (en) 1999-07-13
CA2246072A1 (en) 1997-08-07
US6183977B1 (en) 2001-02-06
HUP9903578A2 (en) 2000-02-28
ES2262153T3 (en) 2006-11-16
AU4632396A (en) 1997-08-22
PL328518A1 (en) 1999-02-01
EP0880700B1 (en) 2006-03-29
EP0880700A1 (en) 1998-12-02
AU712180B2 (en) 1999-10-28
ATE322013T1 (en) 2006-04-15

Similar Documents

Publication Publication Date Title
CA2673314C (en) Non-denaturing lysis reagent for use with capture-in-solution immunoassay
US5482841A (en) Evaluation of transplant acceptance
WO2012161288A1 (en) Immunoassay methods and reagents for decreasing nonspecific binding
JP2000510581A (en) Platelet count assay using platelet granule protein
US6824988B2 (en) Method and compositions for use in diagnosing and characterizing chronic immune disease
AU712180B2 (en) Method of determining the hepatic status of an individual, including a liver transplant recipient
EP0968429A1 (en) Method and kit for determining the phenotype of a haptoglobin and use thereof
RU2164027C2 (en) Method for determining liver state
AU710668B2 (en) Method of determining or detecting donor organ damage following xenotransplantation based on donor-organ derived analytes
AU2006318919A1 (en) Method for identifying the genotype in position 171 of the sheep prion protein as well as kits for implementing said method
JP2000516702A (en) Diagnostic method for detecting the molecular form of eosinophil cationic protein (iso-ECP)
AU2004258830A1 (en) Methods and compositions for use in diagnosing and characterizing diseases involving abnormal apoptosis
RU2157540C2 (en) Method for identifying injuries in donor organ after xenotransplantation by analyzing substances obtained from the donor organ
CA2009643A1 (en) Immunoassay for fhap and antibody useful therewith
WO1993005398A1 (en) Enzyme capture assay
US20100151451A1 (en) Method for Identifying the Genotype in Position 171 of the Ovine Prion Protein as well as Kits for Implementing said Method
WO1996028733A1 (en) Antibody specific for arginase originating in liver and use of the same
JPS62503123A (en) Methods and articles for assaying immune complexes
WO1991008487A1 (en) Method of determining anti-xanthine oxidase antibody

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96199833.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN CZ FI HU JP KR NO NZ PL RU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PV1998-2288

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2246072

Country of ref document: CA

Ref document number: 2246072

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09117476

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1996901946

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996901946

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1998-2288

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV1998-2288

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1996901946

Country of ref document: EP